Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ultracet ER
- Development stage
- Phase 4
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ultracet ER is an extended-release fixed-dose combination of tramadol hydrochloride, a centrally acting atypical opioid analgesic, and acetaminophen (paracetamol), a non-opioid analgesic and antipyretic. Developed by Janssen, this formulation is designed to provide both rapid and prolonged pain relief with improved patient compliance compared to immediate-release formulations. Tramadol exerts its analgesic effects by binding to mu-opioid receptors and weakly inhibiting the reuptake of serotonin and norepinephrine, while acetaminophen acts primarily in the central nervous system to inhibit prostaglandin synthesis. Ultracet ER is indicated for the management of moderate to severe pain, including chronic low back pain, osteoarthritis pain, and postoperative pain.
- Brand names
- Diliban RetardDoreta ProlongDoreta SRUltracet ERUltracet ER Semi TabUltracet ER TabWontran ERWontran Semi ER
- Other names
- acetaminophen + tramadol hydrochloride extended releaseparacetamol + tramadol hydrochloride extended releaseparacetamol/tramadol extended releasetramadol + acetaminophen ERtramadol + acetaminophen extended releasetramadol hydrochloride + acetaminophen extended releasetramadol hydrochloride/acetaminophen ER
02
Targets
MOR (Mu opioid receptor)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on Ultracet ER.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ultracet ER.